- Home
- GNTA vs NSRX Comparison
GNTA vs NSRX Comparison
Compare GNTA & NSRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GNTA | NSRX |
|---|---|---|
| Founded | 2014 | 2019 |
| Country | Italy | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.8M | 38.9M |
| IPO Year | 2021 | 2024 |
Fundamental Metrics
Financial Performance| Metric | GNTA | NSRX |
|---|---|---|
| Price | $0.69 | $3.66 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $19.67 |
| AVG Volume (30 Days) | ★ 53.2K | 14.2K |
| Earning Date | 03-24-2026 | 03-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.55 | $1.98 |
| 52 Week High | $10.00 | $9.50 |
Technical Indicators
Market Signals| Indicator | GNTA | NSRX |
|---|---|---|
| Relative Strength Index (RSI) | 35.23 | 49.56 |
| Support Level | $0.58 | $2.97 |
| Resistance Level | $0.74 | $3.60 |
| Average True Range (ATR) | 0.09 | 0.26 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 29.10 | 64.84 |
Price Performance
Historical ComparisonAbout GNTA Genenta Science S.p.A.
Genenta Science SPA is an industrial consolidator focused on acquiring majority or full ownership of privately held, established companies operating in Italian national-security-regulated sectors. Its acquisition activities span aerospace, defense, national security (including cybersecurity), and biotechnology/biosecurity, with a focus on businesses covered by Italy's Golden Power legislation.
About NSRX Nasus Pharma Ltd. Ordinary Shares
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.